Bill Ackman, founder of Pershing Square, stated that his daughter continues to observe benefits from autologous mitochondrial intraocular injections, although the effects are weaker than the immediate response post-injection. The team is researching ways to increase the frequency of injections.

This statement corresponds to an exploratory treatment for patients with severe bilateral vision loss: the research team extracted the patient's own mitochondria from skeletal muscle in the leg and subsequently injected active mitochondria into the vitreous cavity of both eyes. Research materials indicate that Bill Ackman previously referred to the patient as his daughter, Lucy; the treatment aims to supplement the energy metabolism capacity of damaged but still viable retinal and optic nerve cells.

Existing public data comes from a single-case, non-randomized, uncontrolled preprint case report that has not yet completed peer review. The patient was nearly blind after optic nerve and retinal damage from a brain hemorrhage; 45 consecutive pupil measurements over 71 days prior to treatment did not reach the preset normal light response threshold, but normal range responses appeared post-injection, with 13 out of 52 subsequent measurements reaching the threshold.

The efficacy does not equate to vision restoration. The study recorded the appearance of pupil light responses within days post-injection, and organized responses to visual stimuli were also observed in the brain's visual evoked potentials; the patient reported shape and shadow perception in the left eye during low vision assessments. However, the study did not observe measurable vision improvement, and the immediate light response weakened approximately four weeks later.

Short-term safety is the main known outcome of this case. After injections in both eyes spaced 24 hours apart, researchers did not report intraocular inflammation, increased intraocular pressure, intraocular infection, retinal detachment, or detectable systemic inflammatory responses; this only supports the feasibility and short-term tolerability of the procedure for a single patient and does not prove that repeated injections are equally safe or that the treatment is effective.

The "increased injection frequency" mentioned by Ackman is currently a research direction, not an approved treatment protocol. Public information does not disclose the planned dosing intervals, dosages, trial design, ethical review status, FDA regulatory pathway, or subject recruitment information; any repeated intraocular injections must be individually assessed for risks of infection, intraocular pressure, retinal damage, and immune responses.

In market mechanisms, mitochondrial transplantation has not yet formed an approved ophthalmic therapy, and its current value is primarily concentrated in scientific validation, patents, hospital research platforms, cell preparation, and clinical trial capabilities. If funding continues to flow in this direction, it will first go to institutions capable of GMP-grade autologous mitochondrial separation, quality control, vitreous cavity injection, neuro-ophthalmic assessment, and regulatory submission; patients and investors bear the risks of insufficient evidence, unproven reproducibility, and lack of long-term safety data. Single-case physiological signals can enhance research attention but cannot serve as sufficient evidence for treatment efficacy, commercialization timelines, or biopharmaceutical valuations.

Source: Public Information